AMZN
Amazon.com, Inc.
AMZN has the edge over DAN overall, supported by stronger fundamentals and lower modeled downside.
DAN
Dana Incorporated
DAN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
DAN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Stable |
DAN's profitability is currently healthy, and its revenue and balance sheet are stable, but its cash flow is under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
DAN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 2.4x | $23.26 | — |
| Cheap | 5.9x | $56.02 | +141% |
| Forward | 6.6x | $23.26 | — |
| Fair | 16x | $152 | +553% |
| Expensive | 53x | $506 | +2075% |
Historical ranges are pointers, not guarantees.
DAN has the edge over AMZN in the historical PE scenario, which offers more potential upside but is not a forecast.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over DAN on the outlook, with more favorable profitability expectations.
DAN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for DAN, with profitability holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over DAN on earnings, with more consistent year-over-year improvement.
DAN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.54 | -63% |
| Q3 2026 | $9.55 | +2022% |
| Q2 2026 | $10.05 | +$10.21 |
| Q1 2026 | $10.29 | +$10.53 |
| Q4 2025 | $0.57 | +$0.96 |
| Q3 2025 | $0.45 | +$0.56 |
| Q2 2025 | -$0.16 | -$0.15 |
| Q1 2025 | -$0.24 | -367% |
| Q4 2024 | -$0.39 | -250% |
DAN earned $9.55 per share over the past year, more than ten times what it earned the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over DAN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over DAN on profitability, with a higher operating margin.
DAN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2B | +6.3% |
| Q2 2026 | $2B | +3.9% |
| Q1 2026 | $1.9B | -21% |
| Q4 2025 | $1.9B | -20% |
| Q3 2025 | $1.9B | -23% |
| Q2 2025 | $1.9B | -29% |
| Q1 2025 | $2.4B | -14% |
| Q4 2024 | $2.3B | -6.4% |
DAN's revenue is recovering but still below its 2023 peak: $2B last quarter, up 6.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.5% | +1.8 points |
| Q2 2026 | 3.8% | +2.9 points |
| Q1 2026 | 1% | -2 points |
| Q4 2025 | 3.3% | +4.9 points |
| Q3 2025 | 2.8% | -0.8 points |
| Q2 2025 | 0.8% | -3 points |
| Q1 2025 | 3.1% | +0.5 points |
| Q4 2024 | -1.5% | -2 points |
DAN's operating margin was 4.5% last quarter, up 1.8 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
DAN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32M | -48% |
| Q2 2026 | -$33M | -1200% |
| Q1 2026 | -$257M | -$145M |
| Q4 2025 | $345M | +132% |
| Q3 2025 | $62M | +$73M |
| Q2 2025 | $3M | -97% |
| Q1 2025 | -$112M | +$60M |
| Q4 2024 | $149M | +9.6% |
DAN has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
DAN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.7% | -4M shares |
| 1 year | -19% | -25.3M shares |
| 3 years | -27% | -39.2M shares |
| 5 years | -28% | -40.7M shares |
| Available history | -27% | -39.6M shares |
DAN has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $200M |
| Q2 2026 | $44M |
| Q1 2026 | $125M |
| Q4 2025 | $211M |
| Q3 2025 | $182M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
DAN spent $580M buying back its own shares over the past year.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over DAN on leverage, with a lower net debt burden relative to earnings.
DAN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 5.7x | High |
| Q2 2025 | 4.9x | High |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 3.3x | Elevated |
DAN's net debt is about 2.1 years of its operating earnings (EBITDA), down from 5.7 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
DAN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.5 | Neutral |
| Stochastic | 7.3 | Oversold |
DAN's weekly RSI is 39 (neutral) and its Stochastic is 7 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
DAN PE vs Consumer Cyclical Sector
| Metric | DAN | Sector median | Relative |
|---|---|---|---|
| PE | 2.4x | 18x | 86% below |
| PE % | 2 | 47 | 45 pts below |
DAN has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over DAN on trend strength, trading above more of its moving averages.
DAN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.0 | 11% below |
| 20 week MA | $27.7 | 16% below |
| 50 week MA | $29.8 | 22% below |
| 100 week MA | $23.2 | 0.4% above |
| 200 week MA | $18.3 | 27% above |
DAN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 27% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over DAN on returns for 2026, with the stronger performance.
DAN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.4 | $19.6 | +6.7% |
| 2021 | $19.6 | $22.5 | +15% |
| 2022 | $22.5 | $14.9 | -34% |
| 2023 | $14.9 | $14.6 | -2.1% |
| 2024 | $14.6 | $11.7 | -20% |
| 2025 | $11.7 | $23.9 | +104% |
| 2026 YTD | $23.9 | $23.3 | -2.6% |
DAN has finished lower in three of the last six years. It's down 2.6% so far in 2026.